Gary Ross
General Practice · Brewer, MENPI 1639130099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $239 and has fallen 52.4% since, to $114 in 2025.
Across 60 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$190
- Pfizer$165
- Merck$135
- Abbott$129
- E.r. Squibb & Sons, L.L.C.$93
- Johnson & Johnson$82
- plus $463 from 15 others
What the payments were for
- Food & beverage$1,24399%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $190 |
| Pfizer | 8 | $165 |
| Merck | 7 | $135 |
| Abbott | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $93 |
| Johnson & Johnson | 4 | $82 |
| Exact Sciences | 3 | $54 |
| Astellas Pharma US Inc | 3 | $54 |
| Novo Nordisk | 2 | $46 |
| AstraZeneca | 2 | $41 |
| Novartis | 2 | $41 |
| Lilly USA, LLC | 2 | $37 |
| AbbVie | 1 | $27 |
| Eisai Inc. | 2 | $25 |
| Amgen | 1 | $25 |
| Indivior Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
How this compares
$1,257 in reported general payments places this provider in the 85th percentile of 323 general practice providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $40,730 |
| EliquisApixaban | 43 | $32,576 |
| TrulicityDulaglutide | 25 | $23,844 |
| JardianceEmpagliflozin | 23 | $19,103 |
| XareltoRivaroxaban | 11 | $18,398 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,025 |
| Repatha SureclickEvolocumab | 12 | $10,817 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $8,427 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $8,349 |
| JanuviaSitagliptin Phosphate | 11 | $5,352 |
| Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol | 11 | $2,187 |
| Rosuvastatin Calcium | 79 | $2,128 |
| Novolog FlexpenInsulin Aspart | 13 | $1,692 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,606 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $1,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $46 | $40,73044 claims |
| PfizerEliquis | $165 | $32,57643 claims |
| Lilly USA, LLCTrulicity | $37 | $23,84425 claims |
| Boehringer IngelheimJardiance | $18 | $19,10323 claims |
| Johnson & JohnsonXarelto | $82 | $18,39811 claims |
| GSKTrelegy Ellipta | $190 | $15,02523 claims |
| MerckJanumet, Januvia | $135 | $13,77926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 323 general practice providers in Maine.
Other general practice in Brewer
- Craig RandBrewer$2K
- Andrea TalientoAugusta$167K
- Arjang DjamaliPortland$49K
- Ryan JeffreyBangor$7K
- Theodore MorganGorham$5K
- Robert McVetySpringvale$5K
- Kenneth BakerNorridgewock$4K
- Kevin HadarYarmouth$4K
- Brian BoyntonYarmouth$3K
- Ryan SmithYork$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.